PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 297 filers reported holding PACIRA PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 9.12 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $235,837 | -12.3% | 7,687 | +52.2% | 0.00% | – |
| Q3 2022 | $269,000 | -4.9% | 5,049 | +3.9% | 0.00% | – |
| Q2 2022 | $283,000 | -27.8% | 4,859 | -5.3% | 0.00% | – |
| Q1 2022 | $392,000 | +56.2% | 5,130 | +23.1% | 0.00% | – |
| Q4 2021 | $251,000 | +10.1% | 4,168 | +2.4% | 0.00% | – |
| Q3 2021 | $228,000 | -83.3% | 4,070 | -79.0% | 0.00% | -100.0% |
| Q2 2015 | $1,367,000 | -17.5% | 19,336 | +3.7% | 0.00% | 0.0% |
| Q1 2015 | $1,656,000 | +12.4% | 18,639 | +12.2% | 0.00% | 0.0% |
| Q4 2014 | $1,473,000 | -7.0% | 16,609 | -3.7% | 0.00% | 0.0% |
| Q2 2014 | $1,584,000 | -87.6% | 17,245 | -90.6% | 0.00% | -83.3% |
| Q1 2014 | $12,775,000 | +29.4% | 182,525 | +6.3% | 0.01% | +20.0% |
| Q4 2013 | $9,872,000 | -67.7% | 171,725 | -72.9% | 0.01% | -68.8% |
| Q3 2013 | $30,528,000 | +12.7% | 634,820 | -32.0% | 0.02% | +6.7% |
| Q2 2013 | $27,078,000 | – | 933,720 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gagnon Advisors, LLC | 251,140 | $19,167,000 | 8.83% |
| GAGNON SECURITIES LLC | 610,933 | $46,626,000 | 7.60% |
| Tamarack Advisers, LP | 205,000 | $15,646,000 | 7.40% |
| Spyglass Capital Management LLC | 1,871,040 | $142,798,000 | 4.88% |
| Lisanti Capital Growth, LLC | 302,413 | $23,080,000 | 2.59% |
| Rock Springs Capital Management LP | 1,000,000 | $76,320,000 | 1.92% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 208,197 | $15,890,000 | 1.76% |
| JABODON PT CO | 49,052 | $3,744,000 | 1.70% |
| Zweig-DiMenna Associates LLC | 166,675 | $12,721,000 | 1.70% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 317,425 | $24,226,000 | 1.63% |